Business Context and Reporting Period
This Form 8-K is filed by Graphite Bio, Inc. (not LENZ Therapeutics, Inc. as indicated in the metadata) on December 11, 2022. The company is a Delaware corporation headquartered in South San Francisco, California, and its common stock trades on the NASDAQ Global Market under the symbol GRPH. The filing reports a specific corporate event rather than a standard financial reporting period.
Key Event
Under Item 8.01 (Other Events), the company announced the presentation of preclinical data for a novel sequencing method used to determine gene editing outcomes at the 64th ASH Annual Meeting.
Financial Metrics
This filing is a Current Report (Form 8-K) regarding a specific event and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
There are no material financial changes reported in this document. The primary update is the dissemination of scientific preclinical data regarding the company's gene editing technology.
Outlook, Risks, and Management Commentary
Management Commentary: The filing incorporates a press release (Exhibit 99.1) detailing the presentation of preclinical data. No forward-looking financial guidance or specific management commentary on financial performance is included in this text.
Risks and Contingencies: No specific risks or contingencies are detailed in this filing beyond the general nature of preclinical data presentation.
Investor Verification Checklist
- Verify the discrepancy between the metadata company name (LENZ Therapeutics) and the actual registrant (Graphite Bio, Inc.).
- Review the attached press release (Exhibit 99.1) for details on the preclinical data presented at the ASH Annual Meeting.
- Consult the company's most recent 10-K or 10-Q filings for actual financial metrics, as this 8-K contains none.
- Confirm the company's status as an Emerging Growth Company (indicated as yes in the filing).